Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

24.1%

13 terminated/withdrawn out of 54 trials

Success Rate

58.1%

-28.4% vs industry average

Late-Stage Pipeline

11%

6 trials in Phase 3/4

Results Transparency

178%

32 of 18 completed trials have results

Key Signals

6 recruiting32 with results7 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2

42(79.2%)

Phase 3

6(11.3%)

Phase 1

3(5.7%)

N/A

2(3.8%)

53Total

Phase 2(42)

Phase 3(6)

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (54)

Showing 20 of 54 trials

NCT03233347Phase 2Active Not Recruiting

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Role: lead

NCT05199285Phase 2Terminated

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Role: lead

NCT05246670Phase 2Active Not Recruiting

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Role: lead

NCT05168163Phase 2Recruiting

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Role: lead

NCT02758717Phase 2Active Not Recruiting

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Role: lead

NCT05194293Phase 2Active Not Recruiting

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Role: lead

NCT03765736Terminated

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Role: lead

NCT02973997Phase 2Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Role: lead

NCT04879368Phase 3Active Not Recruiting

RegoNivo vs Standard of Care Chemotherapy in AGOC

Role: collaborator

NCT02368886Phase 2Completed

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Role: lead

NCT03080883Phase 3Completed

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Role: lead

NCT03043313Phase 2Completed

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Role: collaborator

NCT06160206Phase 2Recruiting

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Role: lead

NCT05910801Phase 2Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Role: lead

NCT04117945Phase 2Active Not Recruiting

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Role: lead

NCT04756401Phase 2Active Not Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Role: lead

NCT06238648Phase 2Recruiting

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Role: lead

NCT05356897Phase 2Withdrawn

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Role: lead

NCT04659044Phase 2Terminated

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Role: lead

NCT02873195Phase 2Completed

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Role: lead